Narcolepsy Drugs Market, Size, Global Forecast 2024-2030, Industry Trends, Share, Growth, Insight, Impact of Inflation, Company Analysis

Narcolepsy Drugs Market size is projected to reach US$ 5.95 Billion by 2030, according to Renub Research. Narcolepsy is a disabling condition characterized by three groups of symptoms: excessive daytime sleepiness (EDS) and irresistible sleep episodes, plus or minus automatic behaviours; cataplexy, a sudden loss of muscle tone triggered by strong emotions such as laughter or humorous experiences; and another abnormal rapid eye movement (REM) sleep manifestation; sleep paralysis and hypnagogic hallucinations; disturbed nocturnal sleep; and parasomnias. The cardinal symptoms are excessive daytime sleepiness, sleep attacks, and cataplexy.

The increasing prevalence of disease, increasing R&D activities & investments, and the introduction of novel therapeutic products are key factors driving market growth. According to the National Institute of Neurological Disorders and Stroke (NINDS) estimates, 135,000 to 200,000 people in the U.S. have narcolepsy. The prevalence of the disease increases with rising stress levels in patients; hence, the number of patients with diagnosed narcolepsy is expected to increase in the coming years.

In July 2023, the FDA conducted a comprehensive review of NLS Pharmaceutics' NLS-1031 research protocol, a critical component of the ongoing AMAZE program exploring the potential of Mazindol ER as a therapeutic solution for narcolepsy.

Meanwhile, in June 2023, RareStone Group, a company specializing in rare diseases, unveiled its ambitious plan to establish China's first-ever rare disease ecosystem. A significant milestone in this endeavour was the approval of pitolisant (Wakix) by the Chinese National Medical Products Administration (NMPA) for treating excessive daytime sleepiness (EDS) and cataplexy in adult narcolepsy patients, signalling a breakthrough in improving narcolepsy care within China.

Narcolepsy Drugs Market is expected to grow at a compound annual growth rate (CAGR) of 8.01% from 2023 to 2030

Other symptoms include sudden muscle weakness while awake that makes a person go limp or unable to move (cataplexy). Narcolepsy is a lifelong problem and cannot be cured completely, but symptoms can improve over time with proper medications and lifestyle changes. Increasing stress among individuals consequently leads to a stressful lifestyle, and an increase in alcohol, tobacco, and other harmful addictive substances is expected to increase the risk of narcolepsy. Drug development for narcolepsy treatment has gained incredible momentum in recent years.

In addition, governments of countries such as India and South Africa are promoting the production of narcolepsy drugs, considering their health benefits, which is further expected to boost the narcolepsy drugs market growth during the forecast period. Moreover, high disposable income and increased awareness about the benefits of narcolepsy drugs are anticipated to promote market development. However, lower stability, poor sustainability of natural colours derived from narcolepsy drugs compared to synthetic dyes, and a lack of awareness regarding the diagnosis and treatment availability is predicted to hinder market growth. There is an increase in the number of programs organized by various organizations mainly to increase awareness, which is anticipated to provide lucrative opportunities for the narcolepsy drugs market. The narcolepsy drugs market size reached US$ 3.47 Billion in 2023.

Daytime sleepiness segment significantly impacts the narcolepsy drugs market

The Narcolepsy Drugs Market is divided into Daytime Extreme Sleepiness, Cataplexies and Other Disease Types. The narcolepsy pharmaceutical market is substantially affected by the daytime sleepiness segment. This particular category plays a pivotal role in shaping the industry's dynamics. Narcolepsy, a neurological disorder characterized by excessive daytime sleepiness, demands effective medications to manage its symptoms. As a result, pharmaceutical companies are constantly innovating to cater to this specific need. With an increasing awareness of narcolepsy and its impact on individuals' lives, the demand for drugs targeting daytime sleepiness continues to rise. This segment's significant influence drives research and development and plays a crucial role in shaping the overall market landscape.

Sodium Oxybate segment dominated in the narcolepsy drug market due to its giant usage in treating narcolepsy symptoms

By Therapeutic Type, the Narcolepsy Drugs Market is segmented into Central Nervous system stimulants, Tricyclic Antidepressants, Sodium Oxybate, Selective Serotonin Reuptake inhibitors and others. The sodium oxybate section performed a pivotal position in the narcolepsy drugs market. This prominence stems from its efficacy in dealing with narcolepsy signs and symptoms, inclusive of immoderate daytime sleepiness and cataplexy, function of this neurological disease.

Sodium oxybate, also known as gamma-hydroxybutyrate (GHB), proved to be a cornerstone in narcolepsy drug, extensively improving the lifestyles for those affected. Its unique mechanism of action in regulating sleep patterns and decreasing cataplexy incidents made it a pass-to alternative for healthcare companies and patients. Sodium oxybate section commanded a large market proportion and showcased the importance of tailored treatments in addressing complicated medical conditions like narcolepsy. In May 2023, the Food and Drug Administration (FDA) formally authorized Lumryz (sodium oxybate) to treat cataplexy and immoderate daylight sleepiness in adult narcolepsy patients.

Diagnostic Centers market secured the majority of the revenue share

By End User, Narcolepsy Drugs Market is classified into Hospitals, Diagnostics Centers, and Others. In the narcolepsy drugs market, the Diagnostics Centers sector capturing the lion's revenue share. This segment's prominence is a testomony to its crucial position in diagnosing and treating narcolepsy efficiently. Diagnostics Centers play a pivotal function in identifying the circumstance and tailoring treatment plans to patients, making them a crucial part of the narcolepsy management. Their capacity to offer accurate diagnoses and facilitate the initiation of suitable treatment plans has located them as a cornerstone within the market, underscoring the significance in their contribution in addressing this complicated neurological disorder.

United States leads the narcolepsy drugs marketplace with innovative treatments and tremendous patient care

By country, the Narcolepsy Drugs Market is broken into the United States, Canada, Mexico, Brazil, the United Kingdom, Germany, France, Italy, Spain, the Netherlands, China, Japan, India, South Korea, Australia, South Africa, and the United Arab Emirates. The United States narcolepsy drugs marketplace stands as a robust and influential section in the pharmaceutical industry. With a committed attention on addressing the needs of individuals afflicted via narcolepsy, this market has witnessed significant growth and innovation. Key elements contributing to its prominence consist of advanced research and development, stringent regulatory requirements, and an excessive incidence of narcolepsy cases. Pharmaceutical corporations within the United States continually strive to develop novel drugs and treatment modalities, resulting in an extensive variety of options for narcolepsy control.

Furthermore, the country boasts a well-established healthcare infrastructure, fostering a supportive environment for diagnosis and treatment. Patient focus and advocacy groups also play an important role in using the marketplace forward, making sure that the ones suffering from narcolepsy have get right of access to the latest treatment plans and clinical advancements. All those elements together make the USA narcolepsy drugs market a pacesetter in the global healthcare panorama.

Key Players

Jazz Pharmaceuticals, Ligand Pharmaceuticals, Novartis AG, Takeda Pharmaceutical, Teva Pharmaceutical, Hikma Pharmaceuticals Plc, Harmony Biosciences Holdings and Roche Holding AG are the some of the major company in the Narcolepsy Drugs Market.

Renub Research report titled "Narcolepsy Drugs Market & Global Forecast By Therapeutic Analysis (Central Nervous Systems Stimulants, Tricyclic Antidepressants, Sodium Oxybate, Selective Serotonin Reuptake Inhibitor, Others), Disease (Daytime Extreme Sleepiness, Cataplexia, Other Disease Type), End Users (Diagnostics Centers, Hospitals, Others), Region (North America (United States and Canada), Europe (United Kingdom, Germany, France, Italy, Spain, Netherlands), Asia-Pacific (China, Japan, India, South Korea, Australia), Latin America (Mexico, Brazil), MEA (United Arab Emirates, South Africa)), Company Analysis (Teva Pharmaceutical Industries, Jazz Pharmaceuticals Plc, Novartis AG, LIGAND PHARMACEUTICALS INC, Hikma Pharmaceuticals PLC, Takeda Pharmaceutical Company Limited, Johnson & Johnson, HARMONY BIOSCIENCES)" provides a complete analysis of Global Narcolepsy Drugs Industry.

Therapeutic Analysis - Market has been covered from 5 viewpoints

• 1. Central Nervous Systems Stimulants
• 2. Tricyclic Antiderpressants
• 3. Sodium Oxybate
• 4. Selective Serotonin Reuptake Inhibitor
• 5. Others

Disease - Market has been covered from 3 viewpoints

• 1. Daytime Extreme Sleepiness
• 2. Cataplexia
• 3. Other Disease type

Country - This report covers the 17 countries Narcolepsy Drugs Market

• 1. North America
  • 1.1. United States
  • 1.2. Canada

• 2. Latin America
  • 2.1. Mexico
  • 2.2. Brazil

• 3. Europe
  • 3.1. United Kingdom
  • 3.2. Germany
  • 3.3. France
  • 3.4. Italy
  • 3.5. Spain
  • 3.6. Netherlands

• 4. Asia Pacific
  • 4.1. China
  • 4.2. Japan
  • 4.3. India
  • 4.4. South Korea
  • 4.5. Australia

• 5. Middle East & Africa
  • 5.1. United Arab Emirates
  • 5.2. South Africa

All the major players have been covered 3 Viewpoints

• Overview
• Recent Development
• Net Sales

Company Analysis

• 1. Teva Pharmaceutical Industries
• 2. Jazz Pharmaceuticals Plc
• 3. Novartis AG
• 4. LIGAND PHARMACEUTICALS INC
• 5. Hikma Pharmaceuticals PLC
• 6. Takeda Pharmaceutical Company Limited
• 7. Johnson & Johnson
• 8. HARMONY BIOSCIENCES